Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff ...

Teva (TEVA) is down -12.5%, or -$2.69 to $18.84. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year appears to have investors spooked. Teva on Wednesday reported that ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

NORTH TEXAS — The 100th annual East-West Shrine Bowl kicks off Thursday at AT&T Stadium. The annual meeting of some of the best college football players in the country gives them the opportunity to ...

Walmart has already updated its social media accounts to reflect the new logo and wordmark, leading to critical and confused reactions from users. One shared the “before and after” images of ...